SciSparc Ltd.(SPRC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SPRC SciSparc Ltd.

Closed 07-21 16:00:00 EDT

4.75

+0.05

+1.06%

盘后4.75

+0.000.00%

19:43 EDT

High5.02	Low4.62	Vol10.97K
Open4.78	D1 Closing4.70	Amplitude8.43%
Mkt Cap2.72M	Tradable Cap2.30M	Total Shares573.24K
T/O52.28K	T/O Rate2.26%	Tradable Shares485.10K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SPRC","market":"US","secType":"STK","nameCN":"SciSparc Ltd.","latestPrice":4.75,"timestamp":1784664000000,"preClose":4.7,"halted":0,"volume":10968,"hourTrading":{"tag":"盘后","latestPrice":4.75,"preClose":4.75,"latestTime":"19:43 EDT","volume":65,"amount":305.13,"timestamp":1784677392771,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.010638297872340387,"floatShares":485100,"shares":573243,"eps":-98.07143,"marketStatus":"Closed","change":0.05,"latestTime":"07-21 16:00:00 EDT","open":4.78,"high":5.016,"low":4.62,"amount":52280.496552,"amplitude":0.084255,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-98.07143,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1784707200000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":4.7,"preHourTrading":{"tag":"盘前","latestPrice":4.62,"preClose":4.7,"latestTime":"08:43 EDT","volume":41,"amount":189.6900055,"timestamp":1784637818993,"change":-0.08,"changeRate":-0.017021,"amplitude":0.061702},"postHourTrading":{"tag":"盘后","latestPrice":4.75,"preClose":4.75,"latestTime":"19:43 EDT","volume":65,"amount":305.13,"timestamp":1784677392771,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.204731},"requestUrl":"/m/hq/s/SPRC","defaultTab":"news","newsList":[{"id":"2651546659","title":"SciSparc initiates SCI-110 clinical trial in Germany","url":"https://stock-news.laohu8.com/highlight/detail?id=2651546659","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651546659?lang=en_us&edition=fundamental","pubTime":"2026-07-15 21:06","pubTimestamp":1784120761,"startTime":"0","endTime":"0","summary":"SciSparc (SPRC)announced that its subsidiary NeuroThera Labs announced the initiation of its Phase IIb clinical trial site at Hannover Medical Scho...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scisparc-initiates-sci-110-clinical-trial-in-germany-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scisparc-initiates-sci-110-clinical-trial-in-germany-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","MEDX","IDNA","SPRC","BK4139","BK4007","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651634904","title":"Scisparc: Neurothera Labs Announces Initiation of Phase Iib Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2651634904","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651634904?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:41","pubTimestamp":1784119303,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nFWN43H0W5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRC","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651546310","title":"Scisparc Unit Neurothera Labs Starts Phase Iib Tourette Trial Site at Hannover Medical School","url":"https://stock-news.laohu8.com/highlight/detail?id=2651546310","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651546310?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:41","pubTimestamp":1784119277,"startTime":"0","endTime":"0","summary":"SciSparc unit NeuroThera Labs starts Phase IIb Tourette trial site at Hannover Medical SchoolSciSparc unit NeuroThera Labs initiated a Phase IIb clinical trial site at Hannover Medical School for SCI-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL1kXf46:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","SG9999014005.SGD","BCDF","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014013.SGD","BK4585","IE00BN0W2W23.USD","SPRC","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","BK4007","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU0314104364.USD","SG9999014039.USD","BK4112","NDAQ","LU2210149790.SGD","LU2095319765.USD","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648560559","title":"Neurothera Labs Targets up to C$ 5 Million in Private Placement of Units at C$ 0.135 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2648560559","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648560559?lang=en_us&edition=fundamental","pubTime":"2026-07-01 06:00","pubTimestamp":1782856824,"startTime":"0","endTime":"0","summary":"NeuroThera Labs targets up to C$ 5 million in private placement of units at C$ 0.135 eachNeuroThera Labs launched a non-brokered private placement of up to 37,050,000 units at C$ 0.14 each to raise up","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL82lYdG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SPRC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640615477","title":"SciSparc unit NeuroThera closes purchase of 54% stake in CliniQuantum for CAD 9.46 million in shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2640615477","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640615477?lang=en_us&edition=fundamental","pubTime":"2026-06-04 19:36","pubTimestamp":1780572986,"startTime":"0","endTime":"0","summary":"SciSparc subsidiary NeuroThera Labs closed its purchase of about 54% of Israel-based CliniQuantum.NeuroThera issued 56,600,000 common shares valued at about CAD 9.46 million to acquire 56,375 CliniQuantum shares.Sellers can earn up to USD 2.5 million over three years, tied to patent filings and fundraising milestones.CliniQuantum develops quantum-based analytics for clinical trial data, aiming to identify patient subgroups that respond to therapies.Key asset is an exclusive worldwide license from Quantum X Labs covering a US provisional patent application in quantum Monte Carlo sampling.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief on June 04, 2026, and is ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL8zH0F3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRC","BK4009","BK4139","QXL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640154738","title":"Scisparc: Subsidiary Neurothera Labs Completed Acquisition of Cliniquantum","url":"https://stock-news.laohu8.com/highlight/detail?id=2640154738","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640154738?lang=en_us&edition=fundamental","pubTime":"2026-06-04 19:32","pubTimestamp":1780572720,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nTUA2FT8YD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640901635","title":"SciSparc director Itschak Shrem sells 462 shares for $4,620","url":"https://stock-news.laohu8.com/highlight/detail?id=2640901635","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640901635?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:00","pubTimestamp":1780488058,"startTime":"0","endTime":"0","summary":"SciSparc director Itschak Shrem sold 462 ordinary shares on June 1 at USD 10.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL3Dfqr1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"SciSparc director Itschak Shrem sells 462 shares for $4,620","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRC","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639690209","title":"BUZZ-U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's","url":"https://stock-news.laohu8.com/highlight/detail?id=2639690209","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639690209?lang=en_us&edition=fundamental","pubTime":"2026-05-29 01:41","pubTimestamp":1779990094,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl'sWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ht","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nL6N4250NZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HLXX","SIDU","A","NEOV","BTU","NEBX","NEE","CVX","CGTL","SNPS","P","AU","AMPX","COGT","FANG","HL","HRL","CRM","UNP","APA","PLAB","CDE","CZR","TSN","D","BBY","BURL","DLTR","NEMG","SNOW","NEM","KSS","NBIS","PWR","MASK","HPQ","INKT","LLY","XOM","NSC","ZCMD","MRVL","SUGP","DAVE","MMM","SNOU","SPRC","AVEX","MOD","UMAC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639697490","title":"Why Is SciSparc Stock Skyrocketing On Thursday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2639697490","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639697490?lang=en_us&edition=fundamental","pubTime":"2026-05-29 00:28","pubTimestamp":1779985680,"startTime":"0","endTime":"0","summary":"SciSparc Ltd.  stock is surging on Thursday. The Nasdaq is up 0.63% while the S&P 500 has gained 0.41%.The massive upside comes on the heels of a pre-market announcement detailing a key regulatory milestone achieved by the Tel Aviv-based pharmaceutical player’s majority-owned subsidiary.SciSparc stock is showing exceptional strength. What’s driving SPRC stock higher?SciSparc announced that its subsidiary, NeuroThera Labs Inc., received conditional regulatory approval from the TSX Venture Exchange. The approval clears a path for NeuroThera to acquire an approximate 54% majority stake in CliniQuantum Ltd.Under the terms of the share purchase agreement  previously disclosed in March, NeuroThera will acquire 56,375 ordinary shares of CliniQuantum. In exchange, NeuroThera will issue 56.600 million common shares to the selling shareholders, representing an aggregate value of approximately $9.459 million.CliniQuantum, a private Israeli technology company, develops a platform that applies quan","market":"hk","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=630,dpr=2,format=auto,quality=85/files/images/story/2026/05/28/Man-Hand-With-Stock-Market-Graph-With-Ro_0.jpeg","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=630,dpr=2,format=auto,quality=85/files/images/story/2026/05/28/Man-Hand-With-Stock-Market-Graph-With-Ro_0.jpeg"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/05/52847602/why-is-scisparc-stock-skyrocketing-on-thursday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/05/52847602/why-is-scisparc-stock-skyrocketing-on-thursday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4007","SPRC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638169670","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:30 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2638169670","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638169670?lang=en_us&edition=fundamental","pubTime":"2026-05-28 21:30","pubTimestamp":1779975047,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:30 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nAQN2M0WXI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRC","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638693005","title":"SciSparc unit NeuroThera wins conditional TSX approval for CliniQuantum acquisition update","url":"https://stock-news.laohu8.com/highlight/detail?id=2638693005","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638693005?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:40","pubTimestamp":1779972014,"startTime":"0","endTime":"0","summary":"SciSparc subsidiary NeuroThera Labs received conditional TSX Venture Exchange clearance to buy about 54% of CliniQuantum.NeuroThera plans to issue 56,600,000 common shares valued at about $9.46 million to acquire 56,375 CliniQuantum shares.The deal’s outside date was extended to June 1, 2026, pending an Israeli tax ruling and final TSX acceptance.Earn-out shares will be priced at no less than $0.05 each, with a floor price and seller lock-ups added to the terms.All 56,600,000 consideration shares will be placed in escrow under a Form 5D escrow agreement.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL2J4Lrf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","BK4588","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014039.USD","IE00BKPKM429.USD","SG9999014021.USD","LU2210149790.SGD","BK4139","LU2095319765.USD","BK4112","SPRC","BK4007","LU0314104364.USD","NDAQ","IE00BN0W2V16.EUR","SG9999014005.SGD","IE00B64PRP62.GBP","BK4585","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638693055","title":"Scisparc: Subsidiary Neurothera Labs Received Conditional Regulatory Approval for Acquisition of Cliniquantum","url":"https://stock-news.laohu8.com/highlight/detail?id=2638693055","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638693055?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:40","pubTimestamp":1779972000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUA8HFPR3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","SPRC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634254286","title":"SciSparc regains Nasdaq equity compliance, avoids delisting for now","url":"https://stock-news.laohu8.com/highlight/detail?id=2634254286","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634254286?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:04","pubTimestamp":1778501067,"startTime":"0","endTime":"0","summary":"SciSparc received Nasdaq notice dated Jan. 12, 2026, citing noncompliance with continued listing rule 5550 due to stockholders’ equity below USD 2.5 million.Nasdaq staff also flagged failure to meet alternative continued listing thresholds tied to market value of listed securities at least USD 35 million or net income from continuing operations at least USD 500,000.Conditional compliance letter received May 7, 2026 said the company met rule 5550 based on its annual report for year ended Dec. 31, 2025 filed Apr. 29, 2026.Delisting risk remains if compliance evidence is not shown in the next periodic report filing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL6t1nFt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631524659","title":"Scisparc FY25 net loss widens 94% to USD 12.18 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2631524659","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631524659?lang=en_us&edition=fundamental","pubTime":"2026-04-30 05:07","pubTimestamp":1777496878,"startTime":"0","endTime":"0","summary":"SciSparc posted a net loss attributable to holders of Ordinary Shares of USD 12.18 million, worsening from USD 6.28 million.Revenue fell 35% to USD 856,000, due to operational difficulties that temporarily took Wellution offline from Amazon Marketplace.Operating loss widened 19% to USD 8.37 million.Financial expenses, net swung to an expense of USD 5.92 million from net income of USD 259,000, driven mainly by a USD 5.97 million impairment of loans granted to AutoMax.Outlook: cash and cash equivalents of USD 4.6 million are not sufficient to fund planned operations for at least a year beyond the filing date, raising substantial doubt about ability to continue as a going concern.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Lt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDLQFDK8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRC","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621819650","title":"Scisparc Director Alon Dayan Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2621819650","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621819650?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:01","pubTimestamp":1774296109,"startTime":"0","endTime":"0","summary":"Alon Dayan, a director at SciSparc, filed an initial statement of beneficial ownership reporting 3,651 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 23, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL5lyY4w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","SPRC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620435264","title":"SciSparc Ltd. CEO and CFO Oz Adler Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620435264","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620435264?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:02","pubTimestamp":1773864144,"startTime":"0","endTime":"0","summary":"SciSparc reported an initial statement of beneficial ownership by Oz Adler, an officer serving as CEO and CFO. Adler reported beneficial ownership of 11,058 ordinary shares held directly. Adler also reported a stock option for 6 ordinary shares with an exercise price of USD 21,294.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL2l6j0y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","SPRC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620426449","title":"Scisparc Ltd. Director Moshe Revach Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620426449","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620426449?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:02","pubTimestamp":1773864140,"startTime":"0","endTime":"0","summary":"Moshe Revach filed an initial statement of beneficial ownership as a director of SciSparc. The filing reported beneficial ownership of 3,651 ordinary shares. It also reported a stock option for 1 ordinary share with an exercise price of USD 21,294.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL5Xv7sn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620264487","title":"SciSparc Ltd. Director Amitay Weiss Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620264487","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620264487?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:02","pubTimestamp":1773864138,"startTime":"0","endTime":"0","summary":"SciSparc reported an initial statement of beneficial ownership by director Amitay Weiss. The filing listed 11,058 ordinary shares beneficially owned. It also reported a stock option for 6 ordinary shares with an exercise price of USD 21,294.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL4JWtnc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","SPRC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620264465","title":"Scisparc Ltd. files Form 3 initial beneficial ownership statement for Director Lior Vider","url":"https://stock-news.laohu8.com/highlight/detail?id=2620264465","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620264465?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:02","pubTimestamp":1773864126,"startTime":"0","endTime":"0","summary":"SciSparc reported an initial statement of beneficial ownership by director Lior Vider. The filing shows beneficial ownership of 3,651 ordinary shares. It also reports a stock option for 1 ordinary share with an exercise price of USD 21,294.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL3XqSfb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SPRC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619646878","title":"BRIEF-Scisparc Neurothera Labs- Clearmind Medicine Collaboration Leads To Patent Application For Depression Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2619646878","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619646878?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:21","pubTimestamp":1773663695,"startTime":"0","endTime":"0","summary":"BRIEF-Scisparc Neurothera Labs- Clearmind Medicine Collaboration Leads To Patent Application For Depression TherapyMarch 16 (Reuters) - Scisparc Ltd SPRC.O:SCISPARC: NEUROTHERA LABS- CLEARMIND MEDICIN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA1SQRVZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","SPRC"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.scisparc.com","stockEarnings":[{"period":"1week","weight":0.0284},{"period":"1month","weight":-0.3657},{"period":"3month","weight":-0.2154},{"period":"6month","weight":-0.5026},{"period":"1year","weight":-0.9307},{"period":"ytd","weight":-0.616}],"compareEarnings":[{"period":"1week","weight":-0.0095},{"period":"1month","weight":-0.0062},{"period":"3month","weight":0.054},{"period":"6month","weight":0.0827},{"period":"1year","weight":0.1825},{"period":"ytd","weight":0.0882}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.075328},{"month":2,"riseRate":0.2,"avgChangeRate":-0.14034},{"month":3,"riseRate":0,"avgChangeRate":-0.320237},{"month":4,"riseRate":0.4,"avgChangeRate":0.283936},{"month":5,"riseRate":0.6,"avgChangeRate":-0.008039},{"month":6,"riseRate":0,"avgChangeRate":-0.212405},{"month":7,"riseRate":0,"avgChangeRate":-0.224802},{"month":8,"riseRate":0,"avgChangeRate":-0.467442},{"month":9,"riseRate":0.25,"avgChangeRate":0.236982},{"month":10,"riseRate":0.75,"avgChangeRate":0.077569},{"month":11,"riseRate":0.5,"avgChangeRate":0.007929},{"month":12,"riseRate":0.25,"avgChangeRate":-0.09099}],"exchange":"NASDAQ","name":"SciSparc Ltd.","nameEN":"SciSparc Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SciSparc Ltd.(SPRC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SciSparc Ltd.(SPRC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SciSparc Ltd.,SPRC,SciSparc Ltd.股票,SciSparc Ltd.股票老虎,SciSparc Ltd.股票老虎国际,SciSparc Ltd.行情,SciSparc Ltd.股票行情,SciSparc Ltd.股价,SciSparc Ltd.股市,SciSparc Ltd.股票价格,SciSparc Ltd.股票交易,SciSparc Ltd.股票购买,SciSparc Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SciSparc Ltd.(SPRC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SciSparc Ltd.(SPRC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}